Actively Recruiting
A Randomized Phase 2 Study of Rilvegostomig with Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for First-Line Treatment of HER2-positive Gastric Cancer
Led by AstraZeneca · Updated on 2026-05-12
840
Participants Needed
289
Research Sites
84 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the efficacy and safety of rilvegostomig combined with fluoropyrimidine and trastuzumab deruxtecan (T-DXd) compared to trastuzumab, chemotherapy, and pembrolizumab in patients with HER2-positive locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 CPS ≥ 1. A separate study arm will assess rilvegostomig combined with trastuzumab and chemotherapy to understand the contribution of each treatment component. This is a Phase 2, randomized, open-label, sponsor-blinded clinical trial conducted globally at about 200-250 sites in approximately 25 countries. Participants will be assigned to one of three treatment groups: Arm A receives T-DXd, rilvegostomig, and fluoropyrimidine (capecitabine or 5-FU); Arm B receives pembrolizumab, trastuzumab, and chemotherapy (5-FU plus cisplatin or capecitabine plus oxaliplatin); Arm C receives rilvegostomig, trastuzumab, and chemotherapy (5-FU plus cisplatin or capecitabine plus oxaliplatin). Most drugs are administered by intravenous infusion every three weeks, except capecitabine, which is given orally twice daily. The study compares the effects of these combinations as first-line treatments. Participants will be monitored for up to approximately six years to measure outcomes such as progression-free survival and overall survival. Other assessments include response rates, duration of response, adverse events, pharmacokinetics, immunogenicity, and impact on feeding and side effect burden. The study includes regular evaluations of tumor status using RECIST criteria, organ function, cardiac function, and collection of tumor tissue samples. Safety and treatment effects will be followed closely throughout the study duration.
CONDITIONS
Brief Title
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- HER2 positive for gastric cancer on a tumor biopsy
- PD-L1 combined positive score (CPS) of 1 or higher
- Provide a recent tumor tissue sample adequate for HER2 and PD-L1 testing
- Previously untreated, unresectable, locally advanced or metastatic gastric or GEJ adenocarcinoma
- WHO or ECOG performance status of 0 or 1
- Have measurable target disease based on RECIST v1.1
- Adequate organ and bone marrow function
- Left ventricular ejection fraction (LVEF) of 50% or higher within 28 days before randomization
- Adequate treatment washout period before randomization
You will not qualify if you...
- Lack of physiological integrity of the upper gastrointestinal tract
- Known deficiency of dihydropyrimidine dehydrogenase enzyme
- Contraindication to pembrolizumab, trastuzumab, fluoropyrimidine (5-FU or capecitabine), or platinum (cisplatin or oxaliplatin) treatments
- History of another primary malignancy unless treated with curative intent and no active disease for at least 3 years
- Persistent toxicities from previous anticancer therapy
- Spinal cord compression or brain metastases unless asymptomatic, treated, stable, and not requiring corticosteroids or anticonvulsants
- Uncontrolled infections including tuberculosis and active hepatitis A
- Uncontrolled infections requiring intravenous antibiotics, antivirals, or antifungals
- Recent live attenuated vaccine receipt
- Chronic or active hepatitis B or C infection unless controlled
- Clinically significant cardiac or psychological conditions
- Active or prior autoimmune or inflammatory disorders requiring chronic steroids or immunosuppressive treatment
- History or current interstitial lung disease or pneumonitis or suspected cases not ruled out by imaging
- Lung-specific clinically significant illnesses
- Any active non-infectious skin disease needing systemic treatment
- Pleural effusion, ascites, or pericardial effusion requiring drainage or specific therapies
- History of drug-induced severe skin reactions
- Concurrent anticancer treatments except certain inhibitors
- Recent major surgery or significant trauma or anticipated major surgery during the study
- Use of immunosuppressive medication within 14 days before study intervention
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Until disease progression or unacceptable toxicity
Participants receive assigned study drugs including Rilvegostomig, Trastuzumab deruxtecan, Trastuzumab, Pembrolizumab, Fluoropyrimidine (5-FU or Capecitabine), Cisplatin, or Oxaliplatin intravenously or orally every 3 weeks as part of first-line treatment for HER2-positive gastric cancer.
Infusions every 3 weeks; oral medication taken twice daily as applicable
Duration - Up to approximately 6 years
Participants are monitored for long-term safety and survival outcomes after treatment ends.
Periodic visits for assessments during follow-up
Trial Site Locations
Total: 289 locations
1
Research Site
Anchorage, Alaska, United States, 99508
Actively Recruiting
2
Research Site
Phoenix, Arizona, United States, 85054
Actively Recruiting
3
Research Site
Duarte, California, United States, 91010
Actively Recruiting
4
Research Site
La Jolla, California, United States, 92037
Actively Recruiting
5
Research Site
Los Alamitos, California, United States, 90720
Not Yet Recruiting
6
Research Site
Los Angeles, California, United States, 90089
Actively Recruiting
7
Research Site
Santa Monica, California, United States, 90404
Actively Recruiting
8
Research Site
Solvang, California, United States, 93463
Actively Recruiting
9
Research Site
Upland, California, United States, 91786
Actively Recruiting
10
Research Site
Walnut Creek, California, United States, 94598
Actively Recruiting
11
Research Site
Aurora, Colorado, United States, 80045
Actively Recruiting
12
Research Site
Newark, Delaware, United States, 19713
Not Yet Recruiting
13
Research Site
Jacksonville, Florida, United States, 32207
Not Yet Recruiting
14
Research Site
Jacksonville, Florida, United States, 32224
Actively Recruiting
15
Research Site
Orlando, Florida, United States, 32806
Actively Recruiting
16
Research Site
Athens, Georgia, United States, 30607
Withdrawn
17
Research Site
Marietta, Georgia, United States, 30060
Actively Recruiting
18
Research Site
Chicago, Illinois, United States, 60612
Actively Recruiting
19
Research Site
Chicago, Illinois, United States, 60637
Not Yet Recruiting
20
Research Site
Evanston, Illinois, United States, 60201
Not Yet Recruiting
21
Research Site
Hinsdale, Illinois, United States, 60521
Actively Recruiting
22
Research Site
Niles, Illinois, United States, 60714
Actively Recruiting
23
Research Site
Dyer, Indiana, United States, 46311
Withdrawn
24
Research Site
Waukee, Iowa, United States, 50263
Not Yet Recruiting
25
Research Site
Louisville, Kentucky, United States, 40217
Actively Recruiting
26
Research Site
Silver Spring, Maryland, United States, 20904
Actively Recruiting
27
Research Site
Boston, Massachusetts, United States, 02114
Withdrawn
28
Research Site
Boston, Massachusetts, United States, 02118
Withdrawn
29
Research Site
Detroit, Michigan, United States, 48202
Not Yet Recruiting
30
Research Site
Grand Rapids, Michigan, United States, 49503
Actively Recruiting
31
Research Site
Burnsville, Minnesota, United States, 55337
Actively Recruiting
32
Research Site
Kansas City, Missouri, United States, 64111
Withdrawn
33
Research Site
St Louis, Missouri, United States, 63108
Actively Recruiting
34
Research Site
Omaha, Nebraska, United States, 68198-5885
Not Yet Recruiting
35
Research Site
Reno, Nevada, United States, 89502
Actively Recruiting
36
Research Site
Summit, New Jersey, United States, 07901
Not Yet Recruiting
37
Research Site
Santa Fe, New Mexico, United States, 87505
Actively Recruiting
38
Research Site
New Hyde Park, New York, United States, 11042
Withdrawn
39
Research Site
New York, New York, United States, 10021
Actively Recruiting
40
Research Site
Cincinnati, Ohio, United States, 45220
Actively Recruiting
41
Research Site
Columbus, Ohio, United States, 43210
Not Yet Recruiting
42
Research Site
Philadelphia, Pennsylvania, United States, 19104
Not Yet Recruiting
43
Research Site
Knoxville, Tennessee, United States, 37909
Actively Recruiting
44
Research Site
Nashville, Tennessee, United States, 37232
Withdrawn
45
Research Site
Dallas, Texas, United States, 75246
Actively Recruiting
46
Research Site
Round Rock, Texas, United States, 78665
Not Yet Recruiting
47
Research Site
Webster, Texas, United States, 77598
Actively Recruiting
48
Research Site
Charlottesville, Virginia, United States, 22908
Actively Recruiting
49
Research Site
Fairfax, Virginia, United States, 22031
Actively Recruiting
50
Research Site
Fairfax, Virginia, United States, 22031
Withdrawn
51
Research Site
Richmond, Virginia, United States, 23235
Withdrawn
52
Research Site
Charleston, West Virginia, United States, 25304
Actively Recruiting
53
Research Site
Madison, Wisconsin, United States, 53792
Withdrawn
54
Research Site
Buenos Aires, Argentina, 1264
Not Yet Recruiting
55
Research Site
Ciudad Autónoma Buenos Aires, Argentina, C1430EFA
Actively Recruiting
56
Research Site
Ciudad de Buenos Aires, Argentina, 1280
Actively Recruiting
57
Research Site
Rosario, Argentina, 2123
Actively Recruiting
58
Research Site
Rosario, Argentina, S2000DEJ
Actively Recruiting
59
Research Site
Viedma, Argentina, R8500ACE
Actively Recruiting
60
Research Site
Darlinghurst, Australia, 2010
Actively Recruiting
61
Research Site
Heidelberg, Australia, 3084
Actively Recruiting
62
Research Site
Murdoch, Australia, 6150
Actively Recruiting
63
Research Site
Westmead, Australia, 2145
Actively Recruiting
64
Research Site
Linz, Austria, 4010
Actively Recruiting
65
Research Site
Salzburg, Austria, 5020
Actively Recruiting
66
Research Site
Vienna, Austria, 1090
Actively Recruiting
67
Research Site
Wiener Neustadt, Austria, 2700
Not Yet Recruiting
68
Research Site
Edegem, Belgium, 2650
Actively Recruiting
69
Research Site
Ghent, Belgium, 9000
Actively Recruiting
70
Research Site
Leuven, Belgium, 3000
Actively Recruiting
71
Research Site
Liège, Belgium, 4000
Actively Recruiting
72
Research Site
Barretos, Brazil, 14784-057
Actively Recruiting
73
Research Site
Brasília, Brazil, 71681-603
Actively Recruiting
74
Research Site
Campo Grande, Brazil, 79020-180
Actively Recruiting
75
Research Site
Natal, Brazil, 59075-740
Withdrawn
76
Research Site
Porto Alegre, Brazil, 91350-200
Actively Recruiting
77
Research Site
Recife, Brazil, 50040-000
Actively Recruiting
78
Research Site
Salvador, Brazil, 40170-110
Actively Recruiting
79
Research Site
São Paulo, Brazil, 05652-9000
Actively Recruiting
80
Research Site
Vitória, Brazil, 29043-272
Actively Recruiting
81
Research Site
Calgary, Alberta, Canada, T2N 5G2
Actively Recruiting
82
Research Site
Edmonton, Alberta, Canada, T6G 1Z2
Actively Recruiting
83
Research Site
Winnipeg, Manitoba, Canada, R3E 0V9
Withdrawn
84
Research Site
Barrie, Ontario, Canada, L4M 6M2
Actively Recruiting
85
Research Site
Brampton, Ontario, Canada, L6R 3J9
Not Yet Recruiting
86
Research Site
Hamilton, Ontario, Canada, L8V 5C2
Withdrawn
87
Research Site
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
88
Research Site
Chicoutimi, Quebec, Canada, G7H 5H6
Actively Recruiting
89
Research Site
Montreal, Quebec, Canada, H3A 1A1
Actively Recruiting
90
Research Site
Port Montt, Chile, 5480000
Actively Recruiting
91
Research Site
Rancagua, Chile, 2852424
Not Yet Recruiting
92
Research Site
Santiago, Chile, 7500653
Actively Recruiting
93
Research Site
Santiago, Chile, 7620002
Actively Recruiting
94
Research Site
Santiago, Chile, 8241479
Actively Recruiting
95
Research Site
Temuco, Chile, 4810218
Actively Recruiting
96
Research Site
Viña del Mar, Chile, 2520598
Actively Recruiting
97
Research Site
Anyang, China, 455000
Actively Recruiting
98
Research Site
Beijing, China, 100050
Actively Recruiting
99
Research Site
Beijing, China, CN-100730
Actively Recruiting
100
Research Site
Bengbu, China, 233004
Actively Recruiting
101
Research Site
Changchun, China, 130021
Suspended
102
Research Site
Changsha, China, 410013
Actively Recruiting
103
Research Site
Chengdu, China, 610041
Actively Recruiting
104
Research Site
Fuzhou, China, 350001
Actively Recruiting
105
Research Site
Fuzhou, China, 350014
Actively Recruiting
106
Research Site
Guangzhou, China, 510060
Actively Recruiting
107
Research Site
Guangzhou, China, 510655
Actively Recruiting
108
Research Site
Guangzhou, China, 510700
Actively Recruiting
109
Research Site
Hangzhou, China, 310016
Actively Recruiting
110
Research Site
Harbin, China, 150081
Actively Recruiting
111
Research Site
Hefei, China, 230022
Actively Recruiting
112
Research Site
Hefei, China, 230031
Actively Recruiting
113
Research Site
Jinan, China, 250021
Actively Recruiting
114
Research Site
Kunming, China, 650118
Actively Recruiting
115
Research Site
Lanzhou, China, 730000
Actively Recruiting
116
Research Site
Linfen, China, 041099
Actively Recruiting
117
Research Site
Linyi, China, 276001
Actively Recruiting
118
Research Site
Nanchang, China, 330008
Actively Recruiting
119
Research Site
Nanjing, China, 210009
Actively Recruiting
120
Research Site
Nanjing, China, 210029
Actively Recruiting
121
Research Site
Shandong, China
Actively Recruiting
122
Research Site
Shanghai, China, 200025
Actively Recruiting
123
Research Site
Shanghai, China, 200032
Actively Recruiting
124
Research Site
Shanghai, China, 201114
Actively Recruiting
125
Research Site
Shenyang, China, 110004
Actively Recruiting
126
Research Site
Shenyang, China, 110042
Actively Recruiting
127
Research Site
Shijiazhuang, China, 050000
Actively Recruiting
128
Research Site
Tianjin, China, 300060
Actively Recruiting
129
Research Site
Wenzhou, China, 325000
Actively Recruiting
130
Research Site
Wuhan, China, 430030
Actively Recruiting
131
Research Site
Xi'an, China, 710061
Actively Recruiting
132
Research Site
Xi'an, China, 710068
Actively Recruiting
133
Research Site
Xining, China, 810001
Actively Recruiting
134
Research Site
Yinchuan, China, 750004
Actively Recruiting
135
Research Site
Zhengzhou, China, 450008
Actively Recruiting
136
Research Site
Bordeaux, France, 33076
Not Yet Recruiting
137
Research Site
Caen, France, 14000
Actively Recruiting
138
Research Site
Clermont-Ferrand, France, 63003
Actively Recruiting
139
Research Site
Dijon, France, 21079
Withdrawn
140
Research Site
Lyon, France, 69373
Actively Recruiting
141
Research Site
Marseille, France, 13273
Actively Recruiting
142
Research Site
Poitiers, France, 86021
Withdrawn
143
Research Site
Rennes, France, 35000
Actively Recruiting
144
Research Site
Toulouse, France, 31059
Withdrawn
145
Research Site
Villejuif, France, 94805
Actively Recruiting
146
Research Site
Augsburg, Germany, 86156
Actively Recruiting
147
Research Site
Bad Saarow, Germany, 15526
Actively Recruiting
148
Research Site
Berlin, Germany, 10249
Withdrawn
149
Research Site
Berlin, Germany, 10707
Actively Recruiting
150
Research Site
Berlin, Germany, 13353
Actively Recruiting
151
Research Site
Braunschweig, Germany, 38114
Actively Recruiting
152
Research Site
Chemnitz, Germany, 9116
Actively Recruiting
153
Research Site
Düsseldorf, Germany, 40225
Actively Recruiting
154
Research Site
Essen, Germany, 45122
Actively Recruiting
155
Research Site
Frankfurt, Germany, 60488
Actively Recruiting
156
Research Site
Göttingen, Germany, 37075
Actively Recruiting
157
Research Site
Hamburg, Germany, 20246
Actively Recruiting
158
Research Site
Leipzig, Germany, 04103
Actively Recruiting
159
Research Site
Ludwigshafen, Germany, 67063
Actively Recruiting
160
Research Site
Mannheim, Germany, 68167
Actively Recruiting
161
Research Site
Ulm, Germany, 89081
Actively Recruiting
162
Research Site
Hong Kong, Hong Kong, 150001
Actively Recruiting
163
Research Site
Hong Kong, Hong Kong, 999077
Actively Recruiting
164
Research Site
Hong Kong, Hong Kong
Actively Recruiting
165
Research Site
Hong Kong, Hong Kong
Not Yet Recruiting
166
Research Site
Shatin, Hong Kong, 00000
Not Yet Recruiting
167
Research Site
Budapest, Hungary, 1083
Actively Recruiting
168
Research Site
Budapest, Hungary, 1122
Actively Recruiting
169
Research Site
Budapest, Hungary, 1145
Actively Recruiting
170
Research Site
Gyöngyös, Hungary, 3200
Withdrawn
171
Research Site
Győr, Hungary, 9024
Actively Recruiting
172
Research Site
Gyula, Hungary, 5700
Actively Recruiting
173
Research Site
Zalaegerszeg, Hungary, 8900
Actively Recruiting
174
Research Site
Ansārinagar, India, 110 029
Not Yet Recruiting
175
Research Site
Bangalore, India, 560027
Not Yet Recruiting
176
Research Site
Delhi, India, 110029
Not Yet Recruiting
177
Research Site
Delhi, India, 110085
Actively Recruiting
178
Research Site
Hyderabad, India, 500034
Actively Recruiting
179
Research Site
Kolkata, India, 700094
Actively Recruiting
180
Research Site
Mumbai, India, 400012
Actively Recruiting
181
Research Site
Varanasi, India, 221005
Not Yet Recruiting
182
Research Site
Cagliari, Italy, 09124
Actively Recruiting
183
Research Site
Florence, Italy, 50134
Actively Recruiting
184
Research Site
Milan, Italy, 20162
Actively Recruiting
185
Research Site
Naples, Italy, 80131
Actively Recruiting
186
Research Site
Padova, Italy, 35128
Actively Recruiting
187
Research Site
Rozzano, Italy, 20089
Actively Recruiting
188
Research Site
Torino, Italy, 10126
Actively Recruiting
189
Research Site
Tricase, Italy, 73039
Actively Recruiting
190
Research Site
Akashi-shi, Japan, 673-8558
Actively Recruiting
191
Research Site
Bunkyō City, Japan, 113-8677
Actively Recruiting
192
Research Site
Chūōku, Japan, 104-0045
Actively Recruiting
193
Research Site
Fukuoka, Japan, 811-1395
Actively Recruiting
194
Research Site
Fukuoka, Japan, 812-8582
Actively Recruiting
195
Research Site
Hidaka-shi, Japan, 350-1298
Actively Recruiting
196
Research Site
Hirakata-shi, Japan, 573-1191
Actively Recruiting
197
Research Site
Hiroshima, Japan, 730-8518
Actively Recruiting
198
Research Site
Kasama-shi, Japan, 309-1793
Actively Recruiting
199
Research Site
Kita-gun, Japan, 761-0793
Actively Recruiting
200
Research Site
Kitaadachi-gun, Japan, 362-0806
Actively Recruiting
201
Research Site
Kōtoku, Japan, 135-8550
Actively Recruiting
202
Research Site
Matsuyama, Japan, 791-0280
Actively Recruiting
203
Research Site
Niigata, Japan, 951-8566
Actively Recruiting
204
Research Site
Osaka, Japan, 541-8567
Actively Recruiting
205
Research Site
Osakasayama-shi, Japan, 589-8511
Actively Recruiting
206
Research Site
Ota-shi, Japan, 373-8550
Actively Recruiting
207
Research Site
Sakaishi, Japan, 591-8025
Actively Recruiting
208
Research Site
Sendai, Japan, 980-8574
Actively Recruiting
209
Research Site
Shiwa-gun, Japan, 028-3695
Actively Recruiting
210
Research Site
Suita-shi, Japan, 565-0871
Actively Recruiting
211
Research Site
Sunto-gun, Japan, 411-8777
Actively Recruiting
212
Research Site
Toyoake-shi, Japan, 470-1192
Actively Recruiting
213
Research Site
Yokohama, Japan, 232-0024
Actively Recruiting
214
Research Site
Yokohama, Japan, 241-8515
Actively Recruiting
215
Research Site
George Town, Malaysia, 10450
Actively Recruiting
216
Research Site
Ipoh, Malaysia, 30450
Actively Recruiting
217
Research Site
Kuala Lumpur, Malaysia, 50586
Actively Recruiting
218
Research Site
Kuala Lumpur, Malaysia, 59100
Actively Recruiting
219
Research Site
Sabak Bernam, Malaysia, 88996
Actively Recruiting
220
Research Site
Amsterdam, Netherlands, 1081 HV
Actively Recruiting
221
Research Site
Arnhem, Netherlands, 6815 AD
Actively Recruiting
222
Research Site
Leiden, Netherlands, 2333 ZA
Actively Recruiting
223
Research Site
Arequipa, Peru, AREQUIPA54
Not Yet Recruiting
224
Research Site
Callao, Peru, CALLAO 02
Not Yet Recruiting
225
Research Site
Lima, Peru, 15036
Not Yet Recruiting
226
Research Site
Lima, Peru, LIMA 29
Not Yet Recruiting
227
Research Site
Lima, Peru, Lima 34
Not Yet Recruiting
228
Research Site
Lima, Peru, Lima39
Not Yet Recruiting
229
Research Site
San Isidro, Peru, 15073
Not Yet Recruiting
230
Research Site
Bialystok, Poland, 15-027
Withdrawn
231
Research Site
Gdansk, Poland, 80-219
Actively Recruiting
232
Research Site
Koszalin, Poland, 75-581
Actively Recruiting
233
Research Site
Olsztyn, Poland, 10-228
Actively Recruiting
234
Research Site
Przemyśl, Poland, 37-700
Actively Recruiting
235
Research Site
Warsaw, Poland, 02-034
Actively Recruiting
236
Research Site
Wroclaw, Poland, 50-556
Not Yet Recruiting
237
Research Site
Rio Piedras, Puerto Rico, 00935
Actively Recruiting
238
Research Site
Daegu, South Korea, 41404
Actively Recruiting
239
Research Site
Goyang-si, South Korea, 410-769
Actively Recruiting
240
Research Site
Gyeonggi-do, South Korea, 13620
Actively Recruiting
241
Research Site
Jeonnam, South Korea, 519-763
Actively Recruiting
242
Research Site
Seoul, South Korea, 03080
Actively Recruiting
243
Research Site
Seoul, South Korea, 03722
Actively Recruiting
244
Research Site
Seoul, South Korea, 06351
Actively Recruiting
245
Research Site
Seoul, South Korea, 06591
Actively Recruiting
246
Research Site
Seoul, South Korea, 5505
Actively Recruiting
247
Research Site
Badalona, Spain, 08916
Actively Recruiting
248
Research Site
Barcelona, Spain, 08035
Actively Recruiting
249
Research Site
Madrid, Spain, 28034
Actively Recruiting
250
Research Site
Madrid, Spain, 28041
Actively Recruiting
251
Research Site
Ourense, Spain, 32005
Actively Recruiting
252
Research Site
Santander, Spain, 39008
Actively Recruiting
253
Research Site
Seville, Spain, 41013
Actively Recruiting
254
Research Site
Valencia, Spain, 46010
Actively Recruiting
255
Research Site
Kaohsiung City, Taiwan, 80756
Actively Recruiting
256
Research Site
Kaohsiung City, Taiwan, 824
Actively Recruiting
257
Research Site
Taichung, Taiwan, 40447
Actively Recruiting
258
Research Site
Taichung, Taiwan, 40705
Actively Recruiting
259
Research Site
Tainan, Taiwan, 704
Actively Recruiting
260
Research Site
Tainan, Taiwan, 736
Actively Recruiting
261
Research Site
Taipei, Taiwan, 100
Actively Recruiting
262
Research Site
Taipei, Taiwan, 112
Actively Recruiting
263
Research Site
Taoyuan, Taiwan, 333
Actively Recruiting
264
Research Site
Bangkok, Thailand, 10330
Actively Recruiting
265
Research Site
Bangkok, Thailand, 10400
Actively Recruiting
266
Research Site
Bangkok, Thailand, 10700
Actively Recruiting
267
Research Site
Banphaeo, Thailand, 74120
Actively Recruiting
268
Research Site
Dusit, Thailand, 10300
Actively Recruiting
269
Research Site
Khon Kaen, Thailand, 40002
Actively Recruiting
270
Research Site
Muang, Thailand, 22000
Not Yet Recruiting
271
Research Site
Ankara, Turkey (Türkiye), 06100
Actively Recruiting
272
Research Site
Antalya, Turkey (Türkiye), 07100
Actively Recruiting
273
Research Site
Diyarbakır, Turkey (Türkiye), 21280
Actively Recruiting
274
Research Site
Erzurum, Turkey (Türkiye), 25240
Actively Recruiting
275
Research Site
Istanbul, Turkey (Türkiye), 34010
Actively Recruiting
276
Research Site
Izmir, Turkey (Türkiye), 35965
Actively Recruiting
277
Research Site
Mezitli, Turkey (Türkiye), 33200
Actively Recruiting
278
Research Site
Cambridge, United Kingdom, CB2 2QQ
Actively Recruiting
279
Research Site
Coventry, United Kingdom, CV2 2DX
Actively Recruiting
280
Research Site
Dundee, United Kingdom, DD1 9SY
Actively Recruiting
281
Research Site
London, United Kingdom, EC1A 7BE
Actively Recruiting
282
Research Site
London, United Kingdom, W1G 6AD
Actively Recruiting
283
Research Site
Manchester, United Kingdom, M20 4BX
Actively Recruiting
284
Research Site
Sutton, United Kingdom, SM2 5PT
Actively Recruiting
285
Research Site
Hanoi, Vietnam, 100000
Actively Recruiting
286
Research Site
Ho Chi Minh City, Vietnam, 700000
Actively Recruiting
287
Research Site
Hồ Chí Minh, Vietnam, 700000
Actively Recruiting
288
Research Site
Viet Tri, Vietnam, 35000
Actively Recruiting
289
Research Site
Vinh, Vietnam, 460000
Actively Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here